About Us

Company Overview

Cardiol Therapeutics is a leader in the production of pharmaceutical cannabidiol and the development of innovative cannabidiol medicines for heart disease.

 

The Company is focused on producing pharmaceutical cannabidiol (“CBD”) products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol brings together a wealth of research and development experience, advanced manufacturing capabilities, and a management team, Board of Directors, and Scientific Advisory Board comprising business and thought leaders with extensive industry experience and expertise in commercializing proprietary drugs. Learn more…

We are leveraging our expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.

Our lead product, CardiolRxTM, is designed to be the safest and most consistent cannabidiol formulation on the market. CardiolRxTM is pharmaceutically produced, cGMP certified, and is THC free (<5 ppm). We plan to commercialize CardiolRxTM in the billion-dollar market for medicinal cannabinoids in Canada and we will be pursuing market introduction opportunities in Europe and Latin America. Learn more…

Cardiol is planning an international clinical study of CardiolRxTM in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age and is a common cause of acute heart failure. Learn more…

We are also developing proprietary nanotechnology to deliver pharmaceutical cannabidiol and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated healthcare costs in the U.S. alone exceeding $30 billion. Learn more…

The Company has research programs focused on developing nanotherapeutics to treat heart failure underway at international centers of excellence, including the University of Alberta, the Houston Methodist DeBakey Heart & Vascular Center, and TecSalud del Tecnológico de Monterrey (“TecSalud”). Learn more…

Cardiol has also established an exclusive manufacturing arrangement with Dalton Pharma Services, a Health Canada-approved, U.S. Food and Drug Administration (“FDA”) registered, Current Good Manufacturing Practice (“cGMP”) manufacturer of pharmaceuticals, including cannabinoids, for supplying finished pharmaceutically produced cannabidiol products to support the Corporation’s research and commercial development programs. Cardiol has an exclusive supply agreement with Purisys, LLC to support Dalton’s manufacturing program with large-scale supply of pure pharmaceutical cannabidiol. Learn more…